Edit
Collegium Pharmaceutical, Inc.
http://www.collegiumpharma.com/Last activity: 13.07.2025
Active
Collegium Pharmaceutical is building a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a portfolio of differentiated medications to treat serious medical conditions.
Location: United States, Massachusetts, Stoughton
Employees: 201-500
Total raised: $275.7M
Investors 8
Funding Rounds 3
| Date | Series | Amount | Investors |
| 07.02.2023 | - | $203.2M | - |
| 10.03.2015 | - | $50M | - |
| 22.02.2012 | Series B | $22.5M | - |
Mentions in press and media 9
| Date | Title | Description |
| 16.08.2021 | Collegium Pharmaceutical : Announces $100 Million Share Repurchase Program | STOUGHTON, Mass., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that its Board of Directors ... |
| 22.11.2017 | A scrappy upstart in the pain pill business takes on mighty Purdue Pharma | CANTON, Mass. — Collegium Pharmaceutical, the scrappy upstart taking on the mighty opioid maker Purdue Pharma, is having a moment. The company recently convinced Cigna, Humana, Navitus, and top health insurers in Florida and Pennsylvania to... |
| 11.03.2015 | Collegium Pharmaceutical Raises $50M | CANTON, MA, Specialty pharmaceutical company focused on the development and commercialization of innovative abuse-deterrent treatments for chronic pain and other diseases, has raised a $50 million financing. >> Click here for more ... |
| 10.03.2015 | Collegium Pharmaceutical Raises $50M in Funding | Collegium Pharmaceutical, Inc., a Canton, MA-based specialty pharmaceutical company focused on the development and commercialization of innovative abuse-deterrent treatments for chronic pain and other diseases, raised $50m in funding. The r... |
| 10.03.2015 | Boston Millennia Portfolio Company, Collegium Pharmaceutical Raises $50 million Financing | |
| 29.02.2012 | Tamper-resistant formulation of pain drugs hopes to reduce narcotic abuse | With the series B funding, Collegium will begin a phase 3 clinical study in patients with lower back pain. CEO Michael Heffernan told VentureWire he plans to file a new drug application (NDA) in 2013. COL-003 and COL-172, a similar formulat... |
| 22.02.2012 | Collegium Pharmaceutical Raises $22.5M in Series B Financing | Collegium Pharmaceutical, Inc., a Cumberland, RI-based specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, has raised $22.5m in a Series B financing. The round was led by Longitude Capital ... |
| 04.12.2007 | Life sciences briefing: Tuesday, Dec. 4, 2007 | Featured companies: AgraQuest, BridgeHealth, CardioMems, Collegium Pharmaceutical, Emergin, Entegrion, gDiapers, Precision Therapeutics, PregLem UPDATED: Expanded items on Entegrion, Collegium, and gDiapers. Added CardioMems item. New items... |
| - | Tamper-resistant formulation of pain drugs hopes to reduce narcotic abuse | Making prescription painkillers harder to abuse is the goal of a specialty pharmaceutical company that’s just secured $22.5 million to complete late-stage trials and seek regulatory approval for its tamper-resistant drug technology. Collegi... |